Diamyd Medical AB

Diamyd Medical is a clinical-stage diabetes company active in the field of pharmaceutical development. We develop two novel disease-modifying drugs: the antigenspecific immunotherapy Diamyd and the oral regenerative and immunomodulatory therapeutic Remygen. Diamyd and Remygen are evaluated in ongoing clinical studies. The therapies target the underlying causes of diabetes, dysfunction and loss of the pancreas`s insulin-producing cells. Diamyd Medical’s shares are traded on Nasdaq First North Growth Market, ticker DMYD B.